Tiantan Biotech announced that the holding subsidiary Chengdu Rongsheng plans to acquire 100% of the shares of CSL Asia Pacific's wholly-owned subsidiary Zhongyuan Reed for a total amount of US$185 million, of which the share acquisition consideration was US$137.8 million. The remaining amount of US$47.2 million will be loaned by Chengdu Rongsheng to Zhongyuan Reed to repay CSL Asia Pacific's shareholder loans to Zhongyuan Reed. After the transaction is completed, Zhongyuan Reed will become the company's controlling subsidiary and included in the scope of the company's consolidated financial statements. This transaction does not constitute a related transaction, nor does it constitute a major asset restructuring.

Tiantan Biotech announced that the holding subsidiary Chengdu Rongsheng plans to acquire 100% of the shares of CSL Asia Pacific's wholly-owned subsidiary Zhongyuan Reed for a total amount of US$185 million, of which the share acquisition consideration was US$137.8 million. The remaining amount of US$47.2 million will be loaned by Chengdu Rongsheng to Zhongyuan Reed to repay CSL Asia Pacific's shareholder loans to Zhongyuan Reed. After the transaction is completed, Zhongyuan Reed will become the company's controlling subsidiary and included in the scope of the company's consolidated financial statements. This transaction does not constitute a related transaction, nor does it constitute a major asset restructuring.